Published in J Control Release on October 09, 2015
Metal-Organic Polyhedron Capped with Cucurbit[8]uril Delivers Doxorubicin to Cancer Cells. J Am Chem Soc (2016) 0.78
The potential for tumor suppressor gene therapy in head and neck cancer. Discov Med (2016) 0.77
Identification of a Short Cell-Penetrating Peptide from Bovine Lactoferricin for Intracellular Delivery of DNA in Human A549 Cells. PLoS One (2016) 0.75
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity. J Control Release (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
ABC transporters: from microorganisms to man. Annu Rev Cell Biol (1992) 19.49
Toxic potential of materials at the nanolevel. Science (2006) 19.24
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin (2014) 11.09
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 10.70
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol (2000) 6.90
Emerging applications of stimuli-responsive polymer materials. Nat Mater (2010) 5.94
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Kinetic analysis of translocation through nuclear pore complexes. EMBO J (2001) 5.27
Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett (2009) 4.45
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Aptamers: an emerging class of therapeutics. Annu Rev Med (2005) 4.15
Cancer immunotherapy: a treatment for the masses. Science (2004) 4.04
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res (1970) 3.64
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Aptamers come of age - at last. Nat Rev Microbiol (2006) 3.33
Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer (2007) 3.21
Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res (2000) 3.10
The ancient Virus World and evolution of cells. Biol Direct (2006) 3.06
Non-viral vectors for gene-based therapy. Nat Rev Genet (2014) 3.04
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev (2008) 2.80
Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst (2007) 2.77
Importin beta: conducting a much larger cellular symphony. Mol Cell (2004) 2.75
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
The nuclear pore complex: a protein machine bridging the nucleus and cytoplasm. Curr Opin Cell Biol (2000) 2.56
Causes and consequences of tumour acidity and implications for treatment. Mol Med Today (2000) 2.44
Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ Res (2009) 2.41
Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther (2012) 2.40
Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev (2011) 2.23
Acoustic radiation force in vivo: a mechanism to assist targeting of microbubbles. Ultrasound Med Biol (1999) 2.22
Characterisation of the passive permeability barrier of nuclear pore complexes. EMBO J (2009) 2.21
Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res (2000) 2.17
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release (2009) 2.16
In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res (1993) 2.15
In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small (2008) 2.09
Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol (2008) 2.03
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
Ultrasound-induced cell membrane porosity. Ultrasound Med Biol (2004) 2.00
Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev (2008) 1.93
Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res (1979) 1.93
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
Identification of liver cancer-specific aptamers using whole live cells. Anal Chem (2008) 1.90
Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release (2011) 1.89
Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiology (2007) 1.86
Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther (2006) 1.86
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res (2005) 1.86
Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin (2013) 1.83
Electroporation-based technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng (2014) 1.83
Extracellular pH distribution in human tumours. Int J Hyperthermia (1995) 1.81
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood (2015) 1.72
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release (2005) 1.68
Free radical formation induced by ultrasound and its biological implications. Free Radic Biol Med (1992) 1.67
CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem (2008) 1.65
Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun (2006) 1.64
Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res (2010) 1.60
Remotely triggerable drug delivery systems. Adv Mater (2010) 1.60
Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules (2008) 1.59
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med (2012) 1.54
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res (2006) 1.54
Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem (2008) 1.52
Driving delivery vehicles with ultrasound. Adv Drug Deliv Rev (2008) 1.52
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release (2008) 1.50
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy. Mol Imaging (2006) 1.43
Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics (2008) 1.42
Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res (1996) 1.39
LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat (2006) 1.39
Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res (2006) 1.37
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int J Radiat Oncol Biol Phys (1996) 1.32
Contrast agents for MR imaging of the liver. Radiology (2001) 1.32
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther (2007) 1.27
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood (2005) 1.23
Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials (2013) 1.20
Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients. Radiology (2004) 1.19
Targeted charge-reversal nanoparticles for nuclear drug delivery. Angew Chem Int Ed Engl (2007) 1.18
Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release. J Control Release (2008) 1.16
Gene therapy and DNA delivery systems. Int J Pharm (2013) 1.16
Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier. J Am Chem Soc (2008) 1.14
Dual frequency method for simultaneous translation and real-time imaging of ultrasound contrast agents within large blood vessels. Ultrasound Med Biol (2009) 1.14
Monofunctional and higher-valent platinum anticancer agents. Inorg Chem (2013) 1.13
pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv (2013) 1.13
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
Effect of charge, hydrophobicity, and sequence of nucleoporins on the translocation of model particles through the nuclear pore complex. Proc Natl Acad Sci U S A (2013) 1.11
Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small (2008) 1.11
Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev (2012) 1.11
Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol (2014) 1.10
Amino acid prodrug of quinidine: an approach to circumvent P-glycoprotein mediated cellular efflux. Int J Pharm (2014) 0.82
Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir. Pharmaceuticals (Basel) (2014) 0.79
Prodrug approach to improve absorption of prednisolone. Int J Pharm (2015) 0.75
Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug. Int J Pharm (2016) 0.75
Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release (2017) 0.75